Aurora Receives Expanded Cultivation, Unique Research Licenses for German Facility

EDMONTON, Alberta, July 25, 2024 – PRESS RELEASE – Aurora Cannabis Inc., a leading Canadian-based global medical cannabis company, has been granted two licenses by the Federal Institute for Drugs and Medical Devices (BfArM) under Germany's new Medical Cannabis Act (MedCan-G). Aurora's license grants the company continued domestic cultivation, which has been underway for two years now.

Under the new license, Aurora may also cultivate an approved additional product, and plans to expand its offerings to the rapidly growing German patient base. Aurora will also receive a dedicated R&D license, allowing for the trial of up to seven additional novel cultivars at the company's local EU-GMP facility in Leuna, Germany.

"We thank the German government for its continued investment in the growth of medical cannabis, made possible by decriminalization, which will improve access to medical cannabis for patients all across Germany," Aurora Europe President Michael Simon said. "Being one of the few companies to receive enhanced licenses is a testament to Aurora's established leadership in the region and unparalleled commitment to making available the highest quality cannabis. We now have the framework to extend our portfolio, invest in domestic research and leverage Aurora's global cultivation expertise locally."

Aurora is committed to the growth, acceptance and broader access to medical cannabis globally. The company's leadership in Europe is a result of ongoing collaboration with government, regulators and industry. Since 2021, Aurora's medical cannabis production facility, located in Leuna, Saxony-Anhalt, has been cultivating approximately 1,000 kilograms (about 2,204 pounds) of medical cannabis flower annually as part of a tender agreement with BfArM.

The company has demonstrated a commitment to superior quality and product efficacy that has led to the granting of additional licenses. These additional licenses are a result of the company's continued focus on quality and compliance.

The company supports Germany's investment in meaningful regulatory reform and anticipates it will have broader effect on the expanding acceptance of medical cannabis and future modern frameworks across Europe.

Aurora's domestic and global expertise in developing novel, high-quality and innovative products positions the company as a differentiated leader, poised to fulfill growing patient demand.